Complete financial analysis of OpGen, Inc. (OPGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OpGen, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- ArcLight Clean Transition Corp. II (ACTDW) Income Statement Analysis – Financial Results
- KONE Oyj (KNEBV.HE) Income Statement Analysis – Financial Results
- Un Monde International Ltd. (ARMC) Income Statement Analysis – Financial Results
- V.L. Enterprise Public Company Limited (VL.BK) Income Statement Analysis – Financial Results
- PyroGenesis Canada Inc. (PYR) Income Statement Analysis – Financial Results
OpGen, Inc. (OPGN)
About OpGen, Inc.
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.42M | 2.61M | 4.31M | 4.21M | 3.50M | 2.95M | 3.21M | 4.03M | 3.16M | 4.13M | 2.41M | 5.80M |
| Cost of Revenue | 3.51M | 3.42M | 2.85M | 3.85M | 1.63M | 1.85M | 2.13M | 2.29M | 1.55M | 951.74K | 1.82M | 7.99M |
| Gross Profit | -90.69K | -816.70K | 1.46M | 365.95K | 1.87M | 1.10M | 1.08M | 1.74M | 1.61M | 3.17M | 588.02K | -2.19M |
| Gross Profit Ratio | -2.65% | -31.32% | 33.85% | 8.68% | 53.36% | 37.26% | 33.57% | 43.12% | 50.99% | 76.94% | 24.39% | -37.78% |
| Research & Development | 4.73M | 8.17M | 10.91M | 9.96M | 5.12M | 5.68M | 6.88M | 8.61M | 6.00M | 4.37M | 4.15M | 4.78M |
| General & Administrative | 8.08M | 8.88M | 9.94M | 8.80M | 6.25M | 7.07M | 6.69M | 6.60M | 5.83M | 2.31M | 2.76M | 2.47M |
| Selling & Marketing | 2.78M | 4.34M | 3.71M | 3.09M | 1.46M | 1.53M | 2.75M | 5.53M | 4.31M | 2.06M | 3.05M | 4.27M |
| SG&A | 10.86M | 13.23M | 13.65M | 11.90M | 7.72M | 8.60M | 9.43M | 12.13M | 10.14M | 4.37M | 5.82M | 6.75M |
| Other Expenses | 0.00 | 15.77M | 3.02M | 5.07M | 2.93M | 5.38K | 2.13M | 2,289.90B | 2.07M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.66M | 21.40M | 24.56M | 21.86M | 12.84M | 14.28M | 16.32M | 20.75M | 16.14M | 8.74M | 9.97M | 6.98M |
| Cost & Expenses | 34.17M | 24.83M | 27.41M | 25.71M | 14.47M | 16.13M | 18.45M | 23.04M | 17.69M | 9.69M | 11.79M | 14.97M |
| Interest Income | 142.49K | 46.94K | 45.18K | 105.63K | 9.86K | 5.38K | 0.00 | 0.00 | 26.66K | 156.00 | 1.22K | 114.18K |
| Interest Expense | 1.84M | 3.26M | 4.80M | 3.40M | 187.55K | 191.20K | 233.51K | 149.31K | 1.80M | 111.35K | 31.60K | 0.00 |
| Depreciation & Amortization | 1.32M | 1.64M | 2.71M | 2.33M | 921.38K | 730.88K | 669.09K | 656.05K | 624.65K | 573.92K | 661.81K | 583.72K |
| EBITDA | -29.51M | -32.38M | -20.39M | -19.16M | -10.05M | -12.45M | -14.60M | -18.35M | -13.91M | -4.99M | -9.44M | -8.35M |
| EBITDA Ratio | -863.32% | -850.37% | -535.46% | -507.51% | -313.31% | -447.17% | -474.60% | -472.20% | -439.61% | -120.94% | -361.59% | -144.01% |
| Operating Income | -15.69M | -34.57M | -23.10M | -21.49M | -10.97M | -13.18M | -15.24M | -19.01M | -15.06M | -5.56M | -10.33M | -8.94M |
| Operating Income Ratio | -458.95% | -1,325.77% | -536.51% | -510.02% | -313.59% | -447.35% | -474.60% | -472.20% | -476.90% | -134.86% | -428.54% | -154.07% |
| Total Other Income/Expenses | -16.98M | -15.06M | -11.66M | -4.58M | -1.48M | -187.86K | -153.52K | -157.42K | -2.95M | -106.79K | 195.57K | -345.20K |
| Income Before Tax | -32.67M | -37.28M | -34.76M | -26.08M | -12.45M | -13.37M | -15.39M | -19.17M | -17.48M | -5.67M | -10.13M | -9.28M |
| Income Before Tax Ratio | -955.69% | -1,429.94% | -807.28% | -618.79% | -355.75% | -453.72% | -479.38% | -476.11% | -553.60% | -137.44% | -420.43% | -160.02% |
| Income Tax Expense | 1.00 | -540.30K | 43.83K | 132.40K | -733.83K | -728.84K | -435.58K | -506.73K | -129.10K | 111.35K | 31.60K | 4.93M |
| Net Income | -32.67M | -36.74M | -34.81M | -26.21M | -11.71M | -12.64M | -15.39M | -19.17M | -17.35M | -5.67M | -10.13M | -14.21M |
| Net Income Ratio | -955.69% | -1,409.22% | -808.30% | -621.93% | -334.78% | -428.99% | -479.38% | -476.11% | -549.51% | -137.44% | -420.43% | -244.91% |
| EPS | -41.47 | -150.49 | -189.81 | -331.77 | -144.88 | -841.38 | -3.91K | -10.85K | -13.84K | -5.30K | -9.46K | 0.00 |
| EPS Diluted | -41.47 | -150.49 | -189.81 | -331.77 | -144.88 | -841.38 | -3.91K | -10.85K | -13.84K | -5.30K | -9.46K | 0.00 |
| Weighted Avg Shares Out | 787.83K | 244.16K | 183.37K | 79.00K | 80.85K | 15.02K | 3.93K | 1.77K | 1.25K | 1.07K | 1.07K | 0.00 |
| Weighted Avg Shares Out (Dil) | 787.83K | 244.16K | 183.37K | 79.00K | 80.85K | 15.02K | 3.93K | 1.77K | 1.25K | 1.07K | 1.07K | 0.00 |
OpGen Announces Partial Adjournment of Annual Meeting for Proposal 2 with All Other Proposals Passed
OpGen Group Company Ares Genetics Presents at AWS and Twist Bioscience Webinars
OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q1 2021 Results - Earnings Call Transcript
OpGen, Inc. (OPGN) Reports Q1 Loss, Misses Revenue Estimates
Recap: OpGen Q1 Earnings
OpGen Reports First Quarter 2021 Financial Results and Provides Business Update
OpGen to Provide Business Update and Financial Results for the First Quarter 2021 on May 13th at 8:30 a.m. Eastern Time
OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates (Revised)
Source: https://incomestatements.info
Category: Stock Reports